Akums Drugs and Pharmaceuticals Ltd (AKUMS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Akums Drugs and Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Audio recording of Earning/ Quarterly Conference Call
Audio / Video · 03 Nov 2026, 9:05 pm
Akums Drugs Releases Q2 Audio Recording Link Akums Drugs and Pharmaceuticals Limited has released the audio recording link for its earnings conference call held on 3rd Nov'26 regarding the un-audited financial results for the quarter and half-year ended 30th Sep'26. The company confirmed that the call transcript will subsequently be shared with the stock exchanges and uploaded onto its investor relations website in due course.
Newspaper Publication
Others (Uncategorized) · 03 Nov 2026, 8:15 pm
Akums Drugs Releases Q2 FY27 Financial Results via Newspaper Publication Akums Drugs and Pharmaceuticals Limited published newspaper advertisements on 3rd Nov'26 in the Financial Express and Jansatta pursuant to Regulation 47 of SEBI LODR Regulations. The publication provides QR code access to its standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26, which were approved by the Board of Directors on 2nd Nov'26. Full results and the statutory Limited Review Report are available on the BSE, NSE, and corporate websites.
Final Report of CRISIL Ratings Limited, Monitoring Agency
Others (Uncategorized) · 03 Nov 2026, 7:54 pm
Akums Drugs Achieves 100% IPO Proceeds Utilization in Final Monitoring Report CRISIL Ratings issued its final monitoring agency report for Akums Drugs and Pharmaceuticals Ltd. for the quarter ended 30th Sep'26, confirming 100% utilization of its Rs 6,800.00 mn gross IPO proceeds (revised net proceeds of Rs 6,421.80 mn). Key deployments include Rs 3,870.00 mn toward debt repayment for the company and subsidiaries, Rs 550.00 mn for incremental working capital, Rs 301.80 mn for inorganic acquisitions, and Rs 1,700.00 mn for general corporate purposes. With zero unutilized proceeds remaining, future quarterly monitoring submissions are no longer required.
Q2 FY 2026-27 - Investor Presentation
Investor Presentation · 02 Nov 2026, 11:47 pm
Akums Drugs Reports Strong Q2 FY27 With PAT Surging 168% YoY Akums Drugs & Pharmaceuticals delivered strong Q2 FY27 results, with revenue rising 31.9% YoY to Rs 1,342 cr and EBITDA surging 106.1% YoY to Rs 195 cr (margins expanding 520 bps to 14.5%). PAT jumped 168.3% YoY to Rs 115 cr. Growth was spearheaded by the core CDMO segment (83.1% revenue share), which expanded 38.6% YoY to Rs 1,115 cr with EBITDA of Rs 168 cr. For H1 FY27, revenue reached Rs 2,509 cr (+22.9% YoY) and PAT doubled to Rs 216 cr, driving annualized ROE to 12.2% and ROCE to 19.4%.
Press Release
Press Release · 02 Nov 2026, 11:34 pm
Akums Drugs Reports Strong Q2 FY27 Financial Results Akums Drugs & Pharmaceuticals delivered robust Q2 FY27 results, with revenue growing 31.9% YoY to ₹1,342 crore and PAT surging 168% YoY to ₹115 crore. EBITDA rose 106% YoY to ₹195 crore, expanding margins to 14.5% from 9.3%. The CDMO segment drove growth, with revenue up 38.6% YoY to ₹1,115 crore and EBITDA up 99.6% YoY to ₹168 crore. The company acquired Oriflame India’s manufacturing business for ₹56 crore to enter cosmetics and holds an active pipeline of 30+ European products.
Mr. Sanjay Kumar has been designated as Senior Management Personnel of the Company.
Change in Management · 02 Nov 2026, 11:04 pm
Akums Drugs Reports Strong Q2 FY27 Consolidated Financial Results Akums Drugs and Pharmaceuticals reported a consolidated revenue from operations of ₹13,423.87 million for the quarter ended 30th Sep'26, up 31.9% YoY from ₹10,175.30 million. Net profit attributable to owners surged 176.7% YoY to ₹1,128.51 million compared to ₹407.83 million in the prior-year period. Operating performance was led by its CDMO segment, which generated ₹11,148.66 million in external revenue. The company also fully utilized 100% of its ₹6,800.00 million IPO proceeds and appointed Sanjay Kumar as Senior Management Personnel effective 2nd Nov'26.
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about change in Management
Outcome · 02 Nov 2026, 11:01 pm
Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Unaudited (standalone & consolidated) financial results for the quarter and half year ended on 30th September, 2026'.
Outcome · 02 Nov 2026, 10:59 pm
Unaudited (standalone & consolidated) financial results for the quarter and half year ended on 30th September, 2026
Financial Result · 02 Nov 2026, 10:57 pm
Outcome of the Board Meeting
Outcome · 02 Nov 2026, 10:47 pm
Akums Drugs and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 02 Nov 2026, 10:44 pm
Akums Drugs and Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 13,424 (+31.9% YoY | +15.1% QoQ) ■ EBITDA: 1,947 (+106.1% YoY | +11.5% QoQ) ■ EBITDA Margin (%): 14.5 (+522 bps YoY | -47 bps QoQ) ■ PAT: 1,129 (+176.7% YoY | +12.8% QoQ) ■ EPS (INR): 7.37 (+177.1% YoY | +12.9% QoQ) Akums Drugs and Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) Segmental Performance CDMO ■ Revenue: 11,149 (+38.6% YoY | +15.6% QoQ) ■ EBITDA: 1,682 (+99.6% YoY | +2.9% QoQ) ■ EBITDA Margin (%): 15.1 (+461 bps YoY | -186 bps QoQ) API ■ Revenue: 288 (-35.3% YoY | -9.1% QoQ) ■ EBITDA: -57.4 (+59.1% YoY | -47.1% QoQ) ■ EBITDA Margin (%): -20.0 (+1160 bps YoY | -762 bps QoQ) Domestic branded formulations ■ Revenue: 1,319 (+8.2% YoY | +14.4% QoQ) ■ EBITDA: 240 (-8.9% YoY | +103.2% QoQ) ■ EBITDA Margin (%): 18.2 (-342 bps YoY | +796 bps QoQ) International branded formulations ■ Revenue: 438 (+95.2% YoY | +26.7% QoQ) ■ EBITDA: 99.1 (+80.5% YoY | +43.8% QoQ) ■ EBITDA Margin (%): 22.6 (-184 bps YoY | +268 bps QoQ) Trade generics ■ Revenue: 231 (-5.4% YoY | +10.1% QoQ) ■ EBITDA: 11.9 (Loss to Profit YoY | +746.4% QoQ) ■ EBITDA Margin (%): 5.1 (Loss to Profit YoY | +447 bps QoQ)
Cessation of Mr. Sunil Jaiswal as Senior Management Personnel
Change in Management · 01 Nov 2026, 12:06 am
Akums Drugs Announces Resignation of R&D Senior Vice President Sunil Jaiswal Akums Drugs and Pharmaceuticals Limited has announced the resignation of Mr. Sunil Jaiswal from his role as Senior Vice President – Research & Development and Senior Management Personnel, effective 31st Oct'26. Mr. Jaiswal, aged 61, tendered his resignation on 5th Aug'26 citing personal family commitments. Following discussions, his final relieving date was finalized as 31st Oct'26 to facilitate a smooth transition of his responsibilities.
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 02-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 02 Nov 2026, 5:30 am
Intimation of Schedule of the Investors/Analysts Conference Call (group meet) for un-audited financial results of Q2 FY 2026-27
Intimation · 03 Nov 2026, 12:00 pm
Akums Drugs Schedules Q2 FY27 Earnings Conference Call Akums Drugs and Pharmaceuticals Limited will host an earnings conference call for investors and analysts on 3rd Nov'26 at 12:00 PM IST to discuss its un-audited financial results for Q2 FY27. Key management participants will include Managing Directors Sanjeev Jain and Sandeep Jain, Chief Financial Officer Sumeet Sood, and Head Strategy Sahil Maheshwari. The call will be conducted virtually with dial-in access available via primary numbers +91 22 6280 1488 and +91 22 7115 8869, alongside international toll-free options.
Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve Board Meeting ....
Intimation · 02 Nov 2026, 5:30 am
Akums Drugs Board to Consider Q2 Results on 2nd Nov'26 Akums Drugs and Pharmaceuticals Ltd has scheduled a Board of Directors meeting on 2nd Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. In accordance with SEBI insider trading regulations, the trading window for company securities remains closed and will reopen 48 hours following the declaration of the financial results.
To consider and approve the un-audited (Standalone & Consolidated) financial results for the quarter and half year ended on September 30, 2026
Intimation · 02 Nov 2026, 5:30 am
Demand Notice - National Pharmaceuticals Pricing Authority
Others (Uncategorized) · 15 Oct 2026, 10:08 pm
NPPA Issues Demand Notice to Akums Drugs Subsidiary and Hetero Healthcare Akums Drugs and Pharmaceuticals' wholly-owned subsidiary, Pure and Cure Healthcare, alongside marketer Hetero Healthcare and Abaris Healthcare, received an NPPA demand notice dated 13th Oct'26 for Rs 52.75 cr. The demand relates to alleged DPCO 2013 pricing violations for formulation "Lanol 1000 mg injection" manufactured between Dec'17 and Aug'24, comprising Rs 18.95 cr overcharging, Rs 18.95 cr penalty, and Rs 14.85 cr interest. Akums clarified that primary response liability lies with marketer Hetero Healthcare under contractual indemnity clauses holding marketers solely liable for DPCO breaches.
Intimation of Schedule of the Institutional Investors Meets
Intimation · 23 Sept 2026, 11:39 pm
Akums Drugs Schedules Institutional Investor Meetings in Mumbai Akums Drugs and Pharmaceuticals Limited will participate in physical institutional investor meetings in Mumbai on 28th Sep'26 and 29th Sep'26, starting at 09:00 AM IST onwards. The schedule includes multiple one-on-one and group interactions. The company confirmed that no unpublished price-sensitive information will be shared during these sessions.
Intimation of Schedule of Investors/Analysts Meet
Intimation · 16 Sept 2026, 9:53 pm
Akums Drugs & Pharmaceuticals Schedules Group Investor Meeting on 22nd Sep'26 Akums Drugs and Pharmaceuticals Limited will participate in a physical group investor/analyst meet at the G200 Summit 2026 on 22nd Sep'26, starting at 10:00 AM IST at Taj, Santacruz, Mumbai. The company confirmed that no unpublished price-sensitive information (UPSI) will be shared during the interaction.
Intimation of ESG Rating
Others (Uncategorized) · 03 Sept 2026, 8:32 pm
Akums Drugs Receives Voluntary ESG Rating of 65 for FY26 from NSE Sustainability On 2nd Sep'26, Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY26 from NSE Sustainability Ratings & Analytics Limited. The rating was voluntarily assigned by the agency based solely on publicly available information, as the company did not officially engage NSE Sustainability for this evaluation. This independent ESG assessment provides market participants with a benchmark for the company's environmental, social, and governance practices without active management solicitation.
Intimation of Schedule of the Investors/Analysts Meet
Intimation · 25 Aug 2026, 10:21 pm
Akums Drugs & Pharmaceuticals Announces Investor Meet in Mumbai Akums Drugs & Pharmaceuticals Ltd. will participate in the Ashwamedh – Elara India Dialogue 2026. The physical group meeting with investors and analysts is scheduled for 2nd Sep'26, starting at 02:00 PM (IST) at the Hyatt, Santacruz East, Mumbai. The company confirmed that no unpublished price-sensitive information will be disclosed during this engagement. This event is subject to potential changes.
Akums Drugs and Pharmaceuticals Limited has informed the exchange about an update on schedule of the Investors/ Analysts Meet to be held on August 25, 2026
Intimation · 24 Aug 2026, 8:38 pm
Akums Drugs Cancels Participation in Aug'26 Investor Meet Akums Drugs and Pharmaceuticals (AKUMS) has cancelled its participation in the Investor/Analyst Meet scheduled for Aug 25, 2026. The meeting, organized by Antique Stock Broking Limited in Mumbai, will not feature company personnel due to undisclosed medical reasons. This follows the company's initial confirmation of attendance on Aug 13, 2026. The participation is now officially cancelled.
Intimation of Schedule of the Investors/Analysts Meet
Intimation · 13 Aug 2026, 8:36 pm
Akums Drugs & Pharmaceuticals Schedules Investor Meet in August Akums Drugs & Pharmaceuticals (NSE: AKUMS) will participate in the Antique Healthcare Investor Conference on 25th Aug'26. The physical group meeting is scheduled to begin at 9:00 AM IST at Trident, BKC, Mumbai. Per the company's disclosure dated 13th Aug'26, no unpublished price-sensitive information will be shared during the event. The schedule is subject to potential changes.
Transcript of Investors/Analysts conference call for the unaudited financial results of Q1 FY 27
Transcript · 13 Aug 2026, 8:19 pm
Intimation of Schedule of the Investors/Analysts Meet to be held on August 14, 2026
Intimation · 10 Aug 2026, 10:45 pm
Akums Drugs & Pharmaceuticals to Meet Investors on August 14, 2026 Akums Drugs and Pharmaceuticals will participate in an investor/analyst meet on 14th Aug'26. The company will attend the "Emkay Confluence 2026 - India: Full Throttle Ahead" event. The physical group meeting is scheduled to begin at 09:00 AM IST at the Grand Hyatt in Mumbai. The company has stated that no unpublished price-sensitive information will be shared during the event. This meeting follows standard SEBI disclosure requirements. The schedule is subject to potential changes.